211 lines
59 KiB
HTML
211 lines
59 KiB
HTML
|
<!DOCTYPE html>
|
|||
|
|
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
|||
|
|
<meta charset="utf-8"/>
|
|||
|
|
<meta content="pandoc" name="generator"/>
|
|||
|
|
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
|||
|
|
<title>08 January, 2022</title>
|
|||
|
|
<style type="text/css">
|
|||
|
|
code{white-space: pre-wrap;}
|
|||
|
|
span.smallcaps{font-variant: small-caps;}
|
|||
|
|
span.underline{text-decoration: underline;}
|
|||
|
|
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
|||
|
|
</style>
|
|||
|
|
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
|||
|
|
<body>
|
|||
|
|
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
|||
|
|
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><a href="#from-preprints">From Preprints</a></li>
|
|||
|
|
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
|||
|
|
<li><a href="#from-pubmed">From PubMed</a></li>
|
|||
|
|
<li><a href="#from-patent-search">From Patent Search</a></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><strong>Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background: Neutralising antibody responses to SARS-CoV-2 vaccines have been reported to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We assessed the immunogenicity and safety of a booster dose of BBV152 administered 6 months after the second of a two-dose primary vaccination series. Methods: In an ongoing phase 2 trial (ClinicalTrials.gov: NCT04471519) the protocol was amended after six months to re-consent and randomise 184 previously vaccinated participants to receive a third dose of vaccine or placebo on Day 215. The primary outcome was to measure neutralising antibody titres by plaque-reduction neutralisation test (PRNT50) four weeks after the booster; safety as serious adverse events (SAE) was the key secondary outcome. Findings: Four weeks after a second BBV152 vaccination geometric mean titres (GMTs) of neutralising antibodies were 197.0 PRNT50 (95% CI: 155.6,249.4); this level declined to 23.9 PRNT50 (14.0,40.6) six months later, with a seroconversion rate of 75.4% (95% CI: 68.4,81.6). Four weeks after booster vaccination the GMT increased on Day 243 to 746.6 PRNT50 (514.9,1081) compared with 100.7 PRNT50 (43.6,232.6) in the placebo group. Corresponding seroconversion rates were 98.7% (92.8,99.9) and 79.8% (69.6,87.8). Increased titres in the placebo group were attributed to natural infection as the study was conducted during the second wave of COVID-19 in India. PRNT50 titres against the SARS-CoV-2 variants increased Alpha (32.6 fold), Beta (161.0 fold), Delta (264.7 fold), and Delta plus (174.2 fold) after the booster vaccination. We found that vaccine induces both memory B and T cells with a distinct AIM+ specific CD4+T central and effector memory phenotype, including CD8+ TEMRA phenotype. Reactogenicity after vaccine and placebo was minimal and comparable, and no SAEs were reported. Interpretation: Six months after a two dose BBV152 vaccination series cell mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta and Delta plus) persisted above baseline, although the magnitude of the responses had declined. Neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19 to 97 fold after a third vaccination. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article- link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.05.22268777v1" target="_blank">Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Black Queen rule</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
The nature and dynamics of mutations associated with the emergence, spread and vanishing of SARS-CoV-2 variants causing successive waves are complex. We determined the kinetics of the most common French variant (Marseille-4) for 10 months since its onset in July 2020. Here, we analysed and classified into subvariants and lineages 7,453 genomes obtained by next-generation sequencing. We identified two subvariants, Marseille-4A, which contains 22 different lineages of at least 50 genomes, and Marseille-4B. Their average lifetime was 4.1+/-1.4 months, during which 4.1+/-2.6 mutations accumulated. Growth rate was 0.079+/-0.045, varying from 0.010 to 0.173. All the lineages exhibited a gamma distribution. Several beneficial mutations at unpredicted sites initiated a new outbreak, while the accumulation of other mutations resulted in more viral heterogenicity, increased diversity and vanishing of the lineages. Marseille-4B emerged when the other Marseille-4 lineages vanished. Its ORF8 gene was knocked out by a stop codon, as reported in several mink lineages and in the alpha variant. This subvariant was associated with increased hospitalization and death rates, suggesting that ORF8 is a nonvirulence gene. We speculate that the observed heterogenicity of a lineage may predict the end of the outbreak.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.04.22268715v1" target="_blank">The emergence, spread and vanishing of a French SARS-CoV-2 variant exemplifies the fate of RNA virus epidemics and obeys the Black Queen rule</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
The immune factors associated with impaired SARS-CoV-2 vaccine response in the elderly are mostly unknown. We studied old and young people vaccinated with SARS-CoV-2 BNT162b2 mRNA before and after the first and second dose. Aging was associated with a lower anti-RBD IgG levels and a decreased magnitude and polyfunctionality of SARS-CoV-2 specific T cell response. The dramatic decrease in thymic function in the elderly, which fueled alteration in T cell homeostasis, and lower CD161+ T cell levels were associated with decreased T cell response two months after vaccination. Additionally, a deficient dendritic cell (DC) homing, activation and Toll like receptor (TLR)-mediated function, along with a proinflammatory functional profile in monocytes, were observed in the elderly, which was also related to lower specific T cell response after vaccination. These findings might be relevant for the improvement of the current vaccination strategies and for the development of new vaccine prototypes.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article- html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.07.22268806v1" target="_blank">Innate and adaptive immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in elderly people</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Exploring the health impacts and inequalities of the new way of working: findings from a cross-sectional study.</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Aim To explore the working Welsh adult population9s ability to work from home, their preferences for the future, and the self-reported health impacts of home-working. Subject and Method: A nationally-representative household survey was undertaken across Wales (Public Health Wales9 COVID-19, Employment and Health in Wales study), with cross-sectional data on home-working being collected between November 2020 and January 2021 from 615 employed working-aged adults in Wales (63.7% female, 32.7% aged 50-59). Respondents were asked about their ability to work from home, their perceptions of its impact on their health and their preferences for time spent home-working in future. Results Over 50% were able to work from home, and showed a preference towards home-working to some capacity, with over a third wishing to work from home at least half the time. However, those living in the most deprived areas, in atypical employment, with high wage precarity or with limiting pre-existing conditions were less likely to report being able to work from home. Of those that could work from home, over 40% reported that it worsened their mental well-being and loneliness, and for people in poorer health, home-working negatively impacted their diet, physical activity, smoking and alcohol use. People aged 30 to 39 and those who lived alone were more likely to report wanting to spend some time working in an office/base instead of at home. Conclusion The inequity in the ability to work from home reflects underlying inequalities in Wales, with those facing the greatest insecurity (e.g. those living in most deprived areas, those with more precarious work or financial circumstances) being less able to participate in home-working. Working from home offers greater flexibility, reduces the financial and time costs associated with commuting, and protects individuals from exposure to communicable diseases. However, working from home presents an enormous challenge to preserving the mental-wellbeing of the workforce, particularly for younger individuals and those with low mental well-being. Younger respondents and those in poorer health who could work from home were also more likely to engage in health-harming behaviours, and reduce their engagement in health-protective behaviours such as eating well and moving more. Reflecting on the future, providing pathways for accessing work from home arrangements, integrating hybrid models and preparing targeted health support for at risk groups may be best suited to the working population9s preferences and needs.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.07.22268797v1" target="_blank">Exploring the health impacts and inequalities of the new way of working: findings from a cross-sectional study.</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Glycosylation is the most common form of post-translational modification of proteins, critically affecting their structure and function. Using liquid chromatography and mass spectrometry for high-resolution site-specific quantification of glycopeptides coupled with high-throughput artificial intelligence-powered data processing, we analyzed differential protein glyco-isoform distributions of 597 abundant serum glycopeptides and non-glycosylated peptides in 50 individuals who had been seriously ill with COVID-19 and in 22 individuals who had recovered after an asymptomatic course of COVID-19. As additional comparison reference phenotypes, we included 12 individuals with a history of infection with a common cold coronavirus, 16 patients with bacterial sepsis, and 15 healthy subjects without history of coronavirus exposure. We found statistically significant differences, at FDR<0.05, for normalized abundances of 374 of the 597 peptides and glycopeptides interrogated, between symptomatic and asymptomatic COVID-19 patients. Similar statistically significant differences were seen when comparing symptomatic COVID-19 patients to healthy controls (350 differentially abundant peptides and glycopeptides) and common cold coronavirus seropositive subjects (353 differentially abundant peptides and glycopeptides). Among healthy controls and sepsis patients, 326 peptides and glycopeptides were found to be differentially abundant, of which 277 overlapped with biomarkers that showed differential expression between symptomatic COVID-19 cases and healthy controls. Among symptomatic COVID-19 cases and sepsis patients, 101 glycopeptide and peptide biomarkers were found to be statistically significantly abundant. Using both supervised and unsupervised machine learning techniques, we found specific glycoprotein profiles to be strongly predictive of symptomatic COVID-19 infection. LASSO-regularized multivariable logistic regression and K-means clustering yielded accuracies of 100% in an independent test set and of 96% overall, respectively. Our findings are consistent with the interpretation that a majority of glycoprotein modifications observed which are shared among symptomatic COVID-19 and sepsis patients likely represent a generic consequence of a severe systemic immune and inflammatory state. However, there are glyco-isoform changes that are specific and particular to severe COVID-19 infection. These may be representative of either COVID-19-specific consequences or of susceptibility to or predisposition for a severe course of the disease. Our findings support the potential value of glycoproteomic biomarkers in the biomedical understanding, and, potentially, the clinical management of serious acute infectious conditions.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.07.21267956v1" target="_blank">Differential Peripheral Blood Glycoprotein Profiles in Symptomatic and Asymptomatic COVID-19</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Consensus on COVID-19 vaccination in pediatric oncohematological patients, on behalf of infectious working group of Italian Association of Pediatric Hematology Oncology</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Vaccines represent the best tool to prevent the severity course and fatal consequences of pandemic by new Coronavirus 2019 infection (SARS CoV 2). Considering the limited data on vaccination of pediatric oncohematological patients, we develop a Consensus document to support the Italian pediatric hematological oncological (AIEOP) centers in a scientifically correct communication with families and patients and to promote vaccination. The topics of the Consensus were: SARS CoV 2 infection and disease (COVID 19) in the pediatric subject s; COVID 19 vaccines (type, schedule); which and when to vaccinate; contraindications and risk of serious adverse events; rare adverse events; third dose and vaccination after COVID 19; and other general prevention measures. Using the Delphi methodology fo r Consensus, 21 statements and their corresponding rationale were elaborated and discussed with the representatives of 31 centers, followed by voting. AIEOP Centers showed an overall agreement on all the statements that were therefore approved. This consensus document highlights that children and adolescents affected by hematological and oncological diseases are a fragile category. Vaccination plays an important role to prevent COVID19, to permit the regular administration of chemotherapy or other treatmen ts, to perform control visits and hospital admissions, and to prevent treatment delays.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.06.22268792v1" target="_blank">Consensus on COVID-19 vaccination in pediatric oncohematological patients, on behalf of infectious working group of Italian Association of Pediatric Hematology Oncology</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
Background The recently emerged SARS-CoV-2 omicron variant raised concerns around potential escape from vaccine- elicited immunity. Limited data are available on real-world vaccine effectiveness (VE) of mRNA-1273 against omicron. Here, we report VE of 2 or 3 mRNA-1273 doses against infection and hospitalization with omicron and delta, including among immunocompromised individuals. Methods This test negative study was conducted at Kaiser Permanente Southern California. Cases were individuals aged ≥18 years testing positive by RT-PCR with specimens collected between 12/6/2021 and 12/23/2021 with variant determined by spike gene status. Randomly sampled test negative controls were 5:1 matched to cases by age, sex, race/ethnicity, and specimen collection date. Conditional logistic regression models were used to evaluate adjusted odds ratio (aOR) of vaccination with mRNA-1273 doses between cases and controls. VE(%) was calculated as (1-aOR)x100. Results 6657 test positive cases (44% delta, 56% omicron) were included. The 2-dose VE against omicron infection was 30.4% (95% CI, 5.0%-49.0%) at 14-90 days after vaccination and declined quickly thereafter. The 3-dose VE was 95.2% (93.4%-96.4%) against delta infection and 62.5% (56.2%-67.9%) against omicron infection. The 3-dose VE against omicron infection was low among immunocompromised individuals (11.5%; 0.0%-66.5%). None of the cases (delta or omicron) vaccinated with 3 doses were hospitalized compared to 53 delta and 2 omicron unvaccinated cases. Conclusions VE of 3 mRNA-1273 doses against infection with delta was high and durable, but VE against omicron infection was lower. VE against omicron infection was particularly low among immunocompromised individuals. No 3-dose recipients were hospitalized for COVID-19.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.01.07.22268919v1" target="_blank">Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Statewide Impact of COVID-19 on Social Determinants of Health - A First Look: Findings from the Survey of the Health of Wisconsin</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
There is an urgent need to track the early and ongoing impact of the COVID-19 pandemic on population health from local to global scales. At the same time, there is an overall lack of U.S. state-specific surveillance data tracking social determinants of health (SDOH) and associations with population well-being, individual mitigation and coping strategies, family dynamics and other economic shocks of the pandemic in populations. Statewide data can offer important insights into how SDOH shape the long-term effects of COVID-19 in the population since implementation of many policies and programs varied widely early on in the pandemic. In May of 2020, the Survey of the Health of Wisconsin (SHOW) program launched a statewide online/phone survey of early and ongoing impacts of COVID-19 on health and well-being across diverse communities and families. The goal of this study is to provide descriptive data including perceived COVID-19 risks, access to and results of COVID-19 antigen testing, individual mitigation and coping strategies, family dynamics and other economic shocks of the pandemic on health and mental health in populations. Key findings include higher rates of testing and perceived past infection from COVID-19 among non-white respondents. Higher economic shifts and job changes in female vs male respondents. Families with children reported overall higher levels of stress, and stress from the pandemic. There were urban and rural differences in changes to access to care. Rural regions, which had a lower prevalence of infections early in the pandemic as compared to urban areas, also reported fewer delays or missed appointments due to COVID-19. Key findings show that SDOH are shaping impacts of health and well-being early on in the pandemic and future longitudinal follow-up will be important to shape policies and programs well into the future.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.02.18.21252017v2" target="_blank">Statewide Impact of COVID-19 on Social Determinants of Health - A First Look: Findings from the Survey of the Health of Wisconsin</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Establishing priorities for Pennsylvania community flood resilience</strong> -
|
|||
|
|
<div>
|
|||
|
|
This white paper provides an overview of priorities related to community resilience to flooding that emerged during a 27 September 2019 meeting with local, regional and state representatives in Selinsgrove, Pennsylvania. The document compiles workshop details, participants and a summary of discussions and outcomes. It does not, however, attempt to provide a comprehensive listing of every topic raised by participants. In addition, this workshop was held before the advent of covid-19; the impacts of this pandemic are not addressed in this document.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/qa4z7/" target="_blank">Establishing priorities for Pennsylvania community flood resilience</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>The impact of COVID-19 on hunters in Vietnam, Cambodia, and Laos: a qualitative analysis</strong> -
|
|||
|
|
<div>
|
|||
|
|
The COVID-19 pandemic has accelerated efforts to engage critically with forest-adjacent, rural, communities who rely on wildlife. In this study, we interviewed 109 hunters of wildlife across Vietnam, Cambodia, and Laos regarding the effect the COVID-19 pandemic has had on them individually, as well as more generally within their communities. We found that negative economic impacts such as loss of employment and constrained finances due to rising prices was an especially prevalent theme due to city-wide lockdowns, factory closures, and border closures. In Vietnam, hunting was stated to have increased as young men were forced to return to their villages to work; however, trade in wildlife was believed to have decreased due to the inability of middlemen traders to easily leave urban spaces or cross-country lines. This theme of barriers to trade was found in Cambodia and Laos as well. Our results show the importance of establishing sustainable, non-wildlife-dependent livelihoods within rural communities, to mitigate hunting and mitigate the potential for emerging infectious disease transmission. Overall, our results show the value in engaging with hunters to understand locally and spatially-specific trends, and provide direction for future avenues of research.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/ekyu5/" target="_blank">The impact of COVID-19 on hunters in Vietnam, Cambodia, and Laos: a qualitative analysis</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Mapping Nefarious Social Media Actors to Speed-up Covid-19 Fact-checking</strong> -
|
|||
|
|
<div>
|
|||
|
|
This report presents the outcomes of a project aimed at developing and testing a prototype tool that supports and speeds-up the work of fact-checkers and de-bunkers by surfacing and ranking potentially problematic information circulated on social media with a content-agnostic approach. The tool itself is the result of a multi-year research activity carried on within the Mapping Italian News Research Program of the University of Urbino Carlo Bo to study the strategies, tactics and goals of information operations aimed at manipulating the Italian public opinion by exploiting the vulnerabilities of the contemporary media ecosystem. This research activity led to developing original studies, public reports, new methods, maps and tools employed to study the activity of Italian nefarious social media actors aimed at amplifying the reach and impact of problematic information by coordinating their efforts. Tracking these actors proved instrumental to observe the “infodemic” unraveling during the early days of COVID-19 outbreak in Italy. Combining this existing knowledge with a range of original tools and data sources provided by Meta’s Facebook Open Research Initiative (Fort) and by The International Fact-Checking Network (IFCN) at Poynter, the report: documents those early days by highlighting a list of widely viewed and interacted links circulated on Facebook; traces the establishment, growth and evolution of Italian covid-skeptic coordinated networks on Facebook; presents a comprehensive and updated map of the activities performed by these networks of nefarious social media actors; unveils a set of original tactics and strategies employed by these actors to adjust their operations to the mitigation efforts adopted by social media platforms to reduce the spread of problematic information; describes the circulation of three specific piece of problematic information; provides an overview of the outcomes of the testing phase (carried out in collaboration with Facta.news) of a prototype tool that surfaces and ranks potentially problematic information circulated on social media with a content-agnostic approach.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/6umqs/" target="_blank">Mapping Nefarious Social Media Actors to Speed-up Covid-19 Fact-checking</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>A New Screening Method for COVID-19 based on Ocular Feature Recognition by Machine Learning Tools</strong> -
|
|||
|
|
<div>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
|||
|
|
The Coronavirus disease 2019 (COVID-19) has affected several million people. With the outbreak of the epidemic, many researchers are devoting themselves to the COVID-19 screening system. The standard practices for rapid risk screening of COVID-19 are the CT imaging or RT-PCR (real-time polymerase chain reaction). However, these methods demand professional efforts of the acquisition of CT images and saliva samples, a certain amount of waiting time, and most importantly prohibitive examination fee in some countries. Recently, some literatures have shown that the COVID-19 patients usually accompanied by ocular manifestations consistent with the conjunctivitis, including conjunctival hyperemia, chemosis, epiphora, or increased secretions. After more than four months study, we found that the confirmed cases of COVID-19 present the consistent ocular pathological symbols; and we propose a new screening method of analyzing the eye-region images, captured by common CCD and CMOS cameras, could reliably make a rapid risk screening of COVID-19 with very high accuracy. We believe a system implementing such an algorithm should assist the triage management or the clinical diagnosis. To further evaluate our algorithm and approved by the Ethics Committee of Shanghai public health clinic center of Fudan University, we conduct a study of analyzing the eye-region images of 303 patients (104 COVID-19, 131 pulmonary, and 68 ocular patients), as well as 136 healthy people. Remarkably, our results of COVID-19 patients in testing set consistently present similar ocular pathological symbols; and very high testing results have been achieved in terms of sensitivity and specificity. We hope this study can be inspiring and helpful for encouraging more researches in this topic.
|
|||
|
|
</p>
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2020.09.03.20184226v5" target="_blank">A New Screening Method for COVID-19 based on Ocular Feature Recognition by Machine Learning Tools</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants</strong> -
|
|||
|
|
<div>
|
|||
|
|
SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization when administered early during COVID-19 disease. However, the emergence of variants of concern has negatively impacted the therapeutic use of some authorized mAbs. Using a high throughput B-cell screening pipeline, we isolated a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody called LY-CoV1404 (also known as bebtelovimab). LY-CoV1404 potently neutralizes authentic SARS-CoV-2 virus, including the prototype, B.1.1.7, B.1.351 and B.1.617.2). In pseudovirus neutralization studies, LY-CoV1404 retains potent neutralizing activity against numerous variants including B.1.1.7, B.1.351, B.1.617.2, B.1.427/B.1.429, P.1, B.1.526, and B.1.1.529, and retains binding to spike proteins with a variety of underlying RBD mutations including K417N, L452R, E484K, and N501Y. Structural analysis demonstrates that RBD residues comprising the LY-CoV1404 epitope are highly conserved with the exception of N439 and N501. Notably, the binding and neutralizing activity of LY-CoV1404 is unaffected by the most common mutations at these positions (N439K and N501Y). The breadth of reactivity to amino acid substitutions present among current VOC together with broad and potent neutralizing activity and the relatively conserved epitope suggest that LY-CoV1404 has the potential to be an effective therapeutic agent to treat all known variants causing COVID-19.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.04.30.442182v5" target="_blank">LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li><strong>Digital Platforms in the Emergency Remote Education: the Students’ Preferences</strong> -
|
|||
|
|
<div>
|
|||
|
|
One positive side of the Covid-19 pandemic is the unprecedented opportunity it has offered to the Higher Education Institutions to experience digital learning like never before. During the pandemic, Distant Learning platforms, including Learning Management Systems and Video Conferencing Platforms, have been ubiquitous, and no single institution survived without them during the pandemic. Hence, one of the critical lessons that should be learned is the students’ experiences with these platforms. This study aims to investigate the digital platform preferences of English major students in the College of Language and Translation at King Saud University in Saudi Arabia during the Emergency Remote Education due to the Covid-19 pandemic. Its significance lies in the fact that it underscores and addresses students’ needs and preferences with regard to the digital platforms to be used for language learning, a pragmatic examination of which has been carried out in the following pages. It focuses on reasons for the preferences of the two leading digital platforms used in King Saud University: Blackboard and Zoom. A Survey with open-ended and closed-ended questions was designed to answer the questions of the study: which digital platforms do students prefer to use during Emergency Remote Education, and what were the reasons behind students’ preferences? A total of 300 students from both male and female campuses at different levels of study participated in the study. The results showed that students preferred the Zoom to Blackboard. Reasons of preferences were mainly the ease of use, followed by supporting smartphones, then having an app for smartphones. The thematic analysis of the open-ended question showed that technical problems and connection latency were the main reasons behind students’ preferences of the Zoom. The findings also indicated gender differences in reasons of preferences.
|
|||
|
|
</div>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://osf.io/preprints/socarxiv/5x4ns/" target="_blank">Digital Platforms in the Emergency Remote Education: the Students’ Preferences</a>
|
|||
|
|
</div></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Impact of COVID-19 Forecast Visualizations on Pandemic Risk Perceptions</strong> -
|
|||
|
|
<div>
|
|||
|
|
People worldwide use SARS-CoV-2 (COVID-19) visualizations to make life and death decisions about pandemic risks. Understanding how these visualizations influence risk perceptions to improve pandemic communication is crucial. To examine how COVID-19 visualizations influence risk perception, we conducted two experiments online in October and December of 2020 (N = 2,549) where we presented participants with 34 visualization techniques (available at the time of publication on the CDC’s website) of the same COVID-19 mortality data. We found that visualizing data using a cumulative scale consistently led to participants believing that they and others were at more risk than before viewing the visualizations. In contrast, visualizing the same data with a weekly incident scale led to variable changes in risk perceptions. Further, uncertainty forecast visualizations also affected risk perceptions, with visualizations showing six or more models increasing risk estimates more than the others tested. Differences between COVID-19 visualizations of the same data produce different risk perceptions, fundamentally changing viewers’ interpretation of information.
|
|||
|
|
</div></li>
|
|||
|
|
</ul>
|
|||
|
|
<div class="article-link article-html-link">
|
|||
|
|
🖺 Full Text HTML: <a href="https://psyarxiv.com/6axc7/" target="_blank">Impact of COVID-19 Forecast Visualizations on Pandemic Risk Perceptions</a>
|
|||
|
|
</div>
|
|||
|
|
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Phase III Study of Novaferon in Non-hospitalized Adult Patients With Mild COVID-19</strong> - <b>Condition</b>: Covid19<br/><b>Interventions</b>: Biological: Novaferon; Biological: Placebo<br/><b>Sponsors</b>: Genova Inc.; Tokyo Shinagawa Hospital<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Human COVID-19 immunoglobulin (pH4) for intravenous injection; Drug: Placebo<br/><b>Sponsors</b>: Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.; China National Biotec Group Company Limited; Beijing Tiantan Biological Products Co., Ltd.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Telemedicine Brief Mindfulness Intervention in Post-COVID-19</strong> - <b>Condition</b>: Post COVID-19<br/><b>Intervention</b>: Other: Mindfulness<br/><b>Sponsors</b>: <br/>
|
|||
|
|
Fondazione Don Carlo Gnocchi Onlus; Catholic University of the Sacred Heart<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant; Biological: Saline placebo<br/><b>Sponsors</b>: Cinnagen; Vaxine Pty Ltd<br/><b>Active, not recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Safety, Tolerability, and Efficacy Study of IBI314 in Mild to Moderate Patients With COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: IBI314(low dose); Biological: IBI314(high dose); Biological: IBI314(medium dose); Other: Placebo<br/><b>Sponsor</b>: <br/>
|
|||
|
|
Innovent Biologics (Suzhou) Co. Ltd.<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer- BioNTech COVID-19 Vaccine.</strong> - <b>Condition</b>: Covid19 Vaccine<br/><b>Interventions</b>: Biological: PTX-COVID19-B; Biological: Pfizer- BioNTech COVID-19 vaccine; Biological: Placebo<br/><b>Sponsor</b>: Providence Therapeutics Holdings Inc.<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Quality of Life and Lung Function on Post Covid-19 Patient</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Other: breathing exercise, Aerobic exercises<br/><b>Sponsor</b>: Qassim University<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.</strong> - <b>Condition</b>: SARS CoV 2 Infection<br/><b>Interventions</b>: Drug: Raloxifene; Other: Placebo<br/><b>Sponsor</b>: Dompé Farmaceutici S.p.A<br/><b>Completed</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell)</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Biological: SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated<br/><b>Sponsor</b>: PT. Kimia Farma (Persero) Tbk<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Spa Rehabilitation, Antioxidant and Bioenergetic Supportive Treatment of Patients With Post-Covid-19 Syndrome</strong> - <b>Condition</b>: COVID-19 Respiratory Infection<br/><b>Interventions</b>: Dietary Supplement: ubiquinol (reduced coenzyme Q10); Other: mountain spa rehabilitation; Diagnostic Test: 2x14 ml of peripheral blood collected in a tube with anticoagulant<br/><b>Sponsors</b>: Comenius University; Sanatórium of Dr. Guhr, n.o.<br/><b>Completed</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection</strong> - <b>Condition</b>: COVID-19 Infection<br/><b>Interventions</b>: Other: Nicotinamide Mononucleotide; Other: Nicotinamide Mononucleotide with L-Leucine; Other: Placebo<br/><b>Sponsor</b>: <br/>
|
|||
|
|
Vedic Lifesciences Pvt. Ltd.<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.</strong> - <b>Condition</b>: SARS-CoV-2<br/><b>Interventions</b>: Drug: Sodium Chloride; Biological: NDV- HXP-S IN low dose; Biological: NDV-HXP-S IM low dose; Biological: NDV-HXP-S IN high dose; Biological: NDV- HXP-S IM high dose<br/><b>Sponsor</b>: Sean Liu<br/><b>Recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effectiveness of RPSG Intervention for Nurses During the COVID-19</strong> - <b>Condition</b>: COVID-19 Acute Respiratory Distress Syndrome<br/><b>Interventions</b>: Behavioral: RPSG; Behavioral: AVMBM<br/><b>Sponsor</b>: National Taiwan University Hospital<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial</strong> - <b>Conditions</b>: COVID-19; Long-COVID<br/><b>Interventions</b>: Other: symptom-focused rehabilitation; Other: usual care<br/><b>Sponsors</b>: Schön Klinik Berchtesgadener Land; Bavarian State Office for Health and Food Safety; Praxis im Zentrum Erlangen; Pneumologen Lichterfelde Berlin; Pneumopraxis Marburg; COVID ambulance Philipps-University Marburg; Pneumologie Elisenhof Munich; COVID ambulance Pneumology LMU Munich; COVID ambulance psychology LMU Munich; University Clinic Augsburg; COVID ambulance Schön Klinik Schönau<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)</strong> - <b>Conditions</b>: COVID-19; Coronavirus Infection; SARS CoV 2 Infection<br/><b>Interventions</b>: <br/>
|
|||
|
|
Other: Placebo Comparator: Sterile Water; Other: 27% Ethanol plus essential oils; Other: 0.075% Cetylpyridinium Chloride<br/><b>Sponsor</b>: University of North Carolina, Chapel Hill<br/><b>Not yet recruiting</b></p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Monoclonal antibodies and their target specificity against SARS-CoV-2 infections: Perspectives and challenges Short title: Monoclonal antibodies and SARS-CoV-2 infections</strong> - The world continues to be in the midst of a distressing pandemic of coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel virus with multiple antigenic systems. The virus enters via nasopharynx, oral and infects cells by the expression of the spike protein, and enters the lungs using the angiotensin-converting enzyme-2 receptor. The spectrum of specific immune responses to SARS-CoV-2 virus infection is increasingly…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nucleic Acid-Based Vaccines Platform Against Covid-19 Pandemic</strong> - CONCLUSION: The fast global dissemination of the coronavirus has highlighted the urgent necessity to build an efficient vaccine to inhibit disease. Cooperative attempts throughout the world have paid to the fast and unprecedented production of vaccines. Much needs to be learned regarding SARSCoV-2 and vaccine development against it.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Discovery of compounds inhibiting SARS-COV-2 multi-targets</strong> - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic that has devastated the lives of millions. Researchers around the world are relentlessly working in hopes of finding a cure. Even though the virus shares similarities with reported SARS-CoV and MERS-CoV at the genomic and proteomic level, efforts to repurpose already known drugs against SARS-CoV-2 have resulted ineffective. In this succinct review, we discuss the different potential targets in SARS-CoV-2 at both…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic</strong> - Thousands of drugs, nutraceuticals and their combinations can be used to select candidate therapeutics for targeting SARS-CoV-2 and its symptoms in order to curb COVID-19. A comprehensive, multi-level strategy against COVID-19 should include drug targeting of biomolecules and biochemical pathways involved in the prevention and proliferation of the infection, and the fatal or serious symptoms following infection. Several drugs are routinely used in the treatment of different categories of…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia</strong> - Severe cases of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are associated with elevated blood glucose levels and metabolic complications. However, the molecular mechanisms for how SARS-CoV-2 infection alters glycometabolic control are incompletely understood. Here, we connect the circulating protein GP73 with enhanced hepatic gluconeogenesis during SARS-CoV-2 infection. We first demonstrate that GP73 secretion is induced in multiple tissues upon fasting and that…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment</strong> - The COVID-19 pandemic is one of the greatest threats to human health in the 21st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved. Meanwhile, concentrated efforts of…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Antiviral activity of 5-aminolevulinic acid against variants of severe acute respiratory syndrome coronavirus 2</strong> - CONCLUSION: Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness</strong> - CONCLUSIONS: Our data indicate that R848 administration provides a useful model of ssRNA virus infection, which induces inflammation in the periphery and CNS, and virus infection-like illness. In turn, we show that nafamostat has a systemic anti-inflammatory effect in the presence of the TLR7/8 agonist. Therefore, the results indicate that nafamostat has anti-inflammatory actions, beyond its ability to inhibit TMPRSS2, that might potentiate its anti-viral actions in pathologies such as COVID-19.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Inflammasome activation in neutrophils of patients with severe COVID-19</strong> - Infection by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) engages the inflammasome in monocytes and macrophages and leads to the cytokine storm in COVID-19. Neutrophils, the most abundant leukocytes, release neutrophil extracellular traps (NETs), which have been implicated in the pathogenesis of COVID-19. Our recent study shows that activation of the NLRP3 inflammasome is important for NET release in sterile inflammation. However, the role of neutrophil inflammasome formation…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Cangma Huadu granules, a new drug with great potential to treat coronavirus and influenza infections, exert its efficacy through anti-inflammatory and immune regulation</strong> - CONCLUSION: CMHD can significantly combats viral infections caused by HCoV-229E and H1N1, and the mechanism may be related to its multiple functions of anti-inflammatory, immunity regulating and inhibiting NF-κB signal transduction pathway.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development</strong> - Recognition of viral infections by various pattern recognition receptors (PRRs) activates an inflammatory cytokine response that inhibits viral replication and orchestrates the activation of adaptive immune responses to control the viral infection. The broadly active innate immune response puts a strong selective pressure on viruses and drives the selection of variants with increased capabilities to subvert the induction and function of antiviral cytokines. This revolutionary process dynamically…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sandacrabins - Structurally unique antiviral RNA polymerase inhibitors from a rare myxobacterium</strong> - We report structure elucidation and total synthesis of five unprecedented terpenoid-alkaloids, the sandacrabins, alongside with the first description of their producing organism Sandaracinus defensii MSr10575, which expands the Sandaracineae family by only its second member. The genome sequence of S. defensii as presented in this study was utilized to identify enzymes responsible for sandacrabin formation, whereby dimethylbenzimidazol, deriving from cobalamin biosynthesis, was identified as key…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A novel antagonist of TRPM2 and TRPV4 channels: Carvacrol</strong> - The overload cytosolic free Ca^(2+) (cCa^(2+)) influx-mediated excessive generation of oxidative stress in the pathophysiological conditions induces neuronal and cellular injury via the activation of cation channels. TRPM2 and TRPV4 channels are activated by oxidative stress, and their specific antagonists have not been discovered yet. The antioxidant and anti-Covid-19 properties of carvacrol (CARV) were recently reported. Hence, I suspected possible antagonist properties of CARV against…</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A New Remote Guided Method for Supervised Web-Based Cognitive Testing to Ensure High-Quality Data: Development and Usability Study</strong> - CONCLUSIONS: These data suggest that the RGT methodology could help ameliorate concerns regarding online data quality- particularly for studies involving high-risk or rare cohorts-and offer an alternative for collecting high-quality human cognitive data without requiring in-person physical attendance.</p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro</strong> - Coronavirus disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has set off a global pandemic. There is an urgent unmet need for safe, affordable, and effective therapeutics against COVID-19. In this regard, drug repurposing is considered as a promising approach. We assessed the compounds that affect the endosomal acidic environment by applying human angiotensin-converting enzyme 2 (hACE2)-expressing cells infected with a SARS-CoV-2 spike…</p></li>
|
|||
|
|
</ul>
|
|||
|
|
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
|||
|
|
<ul>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Hung Thanh Phan COVID-19 NEW SOLUTION</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU344983394">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>METHODS OF TREATING SARS-COV-2 INFECTION</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU344309338">link</a></p></li>
|
|||
|
|
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>피라졸 유도체의 폐섬유증 치료제</strong> - 본 발명은 피라졸 유도체인 하기 화학식 1의 화합물 또는 이의 약학적으로 허용가능한 염을 포함하는, 폐섬유증 치료용 약학적 조성물 또는 항바이러스제를 제공한다 <화학식 1></p></li>
|
|||
|
|
</ul>
|
|||
|
|
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">(상기 화학식 1에서 R은 발명의 설명에서 정의한 바와 같다.).</p>
|
|||
|
|
<pre><code> JPEG
|
|||
|
|
pat00008.jpg
|
|||
|
|
72
|
|||
|
|
66 - [link](https://patentscope.wipo.int/search/en/detail.jsf?docId=KR345008871)</code></pre>
|
|||
|
|
<ul>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种疾病相关标志物的筛选方法、应用及试剂盒</strong> - 本发明公开了一种疾病相关标志物的筛选方法、应用及试剂盒。筛选方法包括：使用能够结合免疫球蛋白（Ig）的物质，分别从第一批健康样本血清和患病样本血清中纯化出Ig复合物；将与Ig相结合的蛋白进行蛋白质谱测序分析，比较健康样本与患病样本的差异，找到只出现在患病样本中的差异蛋白，即为该疾病相关潜在标志物。另外还可以通过以下步骤进一步验证该潜在标志物：使用第二批健康样本和患病样本的血清（扩大病例），纯化获得Ig复合物，利用差异蛋白的特异性抗体进行进一步鉴定。该方法先从血清中获得Ig复合物（而不是全血清），再将与Ig相结合的蛋白进行蛋白质谱测序联合特异性抗体分析，能够快速有效地筛选出疾病相关标志物。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN345651106">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种慢性淋巴细胞白血病SSCR风险模型及其建立方法和应用</strong> - 本发明提供一种慢性淋巴细胞白血病SSCR风险模型及其建立方法和应用，属于疾病预后和分子生物学技术领域。本发明采用高通量测序的慢性淋巴细胞白血病(CLL)表达谱，进一步证实CLL的异质性，验证基于CLL细胞分化的CLL患者分类，预测患者预后。本发明将CLL细胞按分化状态分为两组，并对CLL细胞分化相关基因进行鉴定。最后，选择4个最具预后意义的CLL细胞分化相关基因，建立基于CLL细胞分化相关基因的SSCR风险评分模型，经验证该风险评分模型对CLL患者总生存期及首次治疗时间预测具有良好的可靠性。该评分系统可以帮助医生根据CLL细胞分化状况预测患者的预后，选择最佳的治疗方案，具有良好的实际应用价值。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN345651062">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种流感新冠联合疫苗及其制备方法</strong> - 本发明公开了一种流感新冠联合疫苗，包括以下质量浓度的原料：含RBD‑Fc融合蛋白的重组新冠疫苗1‑100μg/mL；含H1N1型流感病毒的流感亚单位疫苗1‑50μg/mL；含H3N2型流感病毒的流感亚单位疫苗1‑50μg/mL；含B型流感病毒的流感亚单位疫苗1‑50μg/mL；氢氧化铝溶液，其中铝离子在流感新冠联合疫苗中的终浓度为0.5‑2.0mg/mL；余量为PBS磷酸缓冲液。制备方法：称取各原料；将四种疫苗分别用PBS磷酸缓冲液稀释后与氢氧化铝溶液混合；按照等体积比例混合，即得。本发明为含铝佐剂的新型冠状病毒疫苗和含铝佐剂的流感亚单位疫苗的联合疫苗，联合后，两种抗原组分疫苗之间没有相互抑制，能很好兼容。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN345598579">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>REAL-TIME REST BREAK MANAGEMENT SYSTEM FOR WORKPLACE</strong> - The present invention relates to a real-time rest break management system for workplace that comprises of a work desk, wherein first portion is incorporated with a biometric unit 4 for authenticating first user, and a second portion with a telescopic panel 2 associated with a weight sensor 6 and timer unit 7 calculating weight of head/hand manifesting user presence and their resting time period is mounted with an inflated cushion 5, an interactive primary display unit 1 attached over desk enables user to set first/second threshold time for sleeping/taking break, further linked with a tracking interface keeping track of activities and a vibrating unit crafted inside the cushion 5 which is linked to a secondary display unit 8 of second user, giving them access to actuate vibrating unit generating impulses to wake first user when threshold time period is exceeded by the first user. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN342791215">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种瑞德西韦的合成方法</strong> - 本发明涉及一种瑞德西韦的合成方法，包括以下步骤：将(2R,3R,4S,5R)‑2‑(4‑氨基吡咯[2,1‑f][1,2,4]三嗪‑7‑基)‑3,4‑二羟基‑5‑(羟甲基)四氢呋喃‑2‑碳腈、2,2‑二甲氧基丙烷和第一酸催化剂加入第一溶剂中，搅拌，经2,2‑二甲氧基丙烷保护邻二羟基合成中间体4，反应完毕后调碱降温；将无水氯化镁和中间体7加入反应中，通氮气流保护，搅拌均匀后滴加碱催化剂，升温搅拌，合成中间体5，反应完毕后进行提取分液；向反应中滴加第二酸催化剂，搅拌，经过后处理得到瑞德西韦粗品。本发明的三步反应均以第一溶剂为介质进行反应，仅在三步反应完成后进行后处理浓缩溶剂，减少浓缩溶剂的次数，降低工业成本。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN345598362">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种基于宏基因组学的病原微生物检测方法及装置</strong> - 本发明公开了一种基于宏基因组学的病原微生物检测方法及装置，包括：获取待检测样本的宏基因组测序数据；对宏基因组测序数据进行预处理，得到目标数据；对目标数据进行筛选，得到目标序列；对目标序列进行聚类分析，获得待测样本的候选物种类别；将目标数据与非冗余参考基因集进行比对，并计算每个基因在单个样本中的丰度，得到待测样本的目标物种分类信息；将目标数据与病原微生物可检测数据库中的信息进行比对，获得待测样本的耐药基因和毒性元件信息；将目标物种分类信息、耐药基因和毒性元件信息，确定为待检测样本的检测结果。本发明提升了病原微生物检测适用性范围和病原检测准确性。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN345598129">link</a></p></li>
|
|||
|
|
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>CONJUNTO DE ESCOBILLA Y ESCOBILLERO CON AUTOLIMPIEZA</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=ES342833480">link</a></p></li>
|
|||
|
|
</ul>
|
|||
|
|
|
|||
|
|
|
|||
|
|
<script>AOS.init();</script></body></html>
|